| Market Cap | 9.81M | P/E | - | EPS this Y | 33.20% | Ern Qtrly Grth | - |
| Income | -37.99M | Forward P/E | -0.39 | EPS next Y | 30.90% | 50D Avg Chg | 41.00% |
| Sales | 329k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -71.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -93.00% |
| Recommedations | 2.30 | Quick Ratio | 2.46 | Shares Outstanding | 11.71M | 52W Low Chg | 411,150.00% |
| Insider Own | 0.41% | ROA | -61.78% | Shares Float | 10.17M | Beta | 1.52 |
| Inst Own | 20.37% | ROE | -508.58% | Shares Shorted/Prior | 311.11K/31.39K | Price | 0.82 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 166,224 | Target Price | 38.33 |
| Oper. Margin | -12,239.21% | Earnings Date | Aug 9 | Volume | 44,894 | Change | 0.00% |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.